Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Official title

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol

Overview

The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.

Detailed description

Participants will continue study treatment until disease progression, death, unacceptable toxicity, participant request to stop treatment, Investigator decision, or study termination by the Sponsor i.e., up to Aapproximately 28 months.

Interventions

• Drug Isatuximab
  Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion
• Drug Dexamethasone
  Pharmaceutical form: Tablet; Route of administration: Oral
• Drug Pomalidomide
  Pharmaceutical form: Capsule; Route of administration: Oral
• Drug Belantamab mafodotin
  Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
• Drug Pegenzileukin
  Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
• Drug SAR439459
  Pharmaceutical form: Solution for injection; Route of administration: Intravenous
• Drug Belumosudil
  Pharmaceutical form: tablet; route of administration: oral
• Drug Evorpacept
  Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Primary outcome measures

• Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximab [Time frame: Through the end of cycle 1 (approximately 6 weeks)]
• Part 2 (expansion, controlled experimental substudies): VGPR Rate (Rate of Very Good Partial Response Rate or Better) [Time frame: Up to approximately 28 months after the First patient in or scheduled assessment]
• Part 2 (expansion, independent experimental substudies): Overall Response Rate (ORR) in independent experimental substudies [Time frame: Up to approximately 28 months after the First patient in or scheduled assessment]

Secondary outcome measures (12)

• Part 1 (dose finding, experimental substudies): ORR [Time frame: Up to approximately 28 months after the First patient in or scheduled assessment]
• Part 2 (expansion, controlled experimental substudies): ORR [Time frame: Up to approximately 28 months after the First patient in or scheduled assessment]
• Part 1 (dose finding, experimental substudies): VGPR or better [Time frame: Up to approximately 28 months after the First patient in or scheduled assessment]
• Part 2 (expansion, independent experimental substudies): VGPR or better [Time frame: Up to approximately 28 months after the First patient in or scheduled assessment]
• Clinical benefit rate (CBR) in each treatment arm [Time frame: Up to approximately 28 months after the First patient in or scheduled assessment]
• Duration of Response (DOR) in each treatment arm [Time frame: Up to approximately 28 months after the First patient in or scheduled assessment]
• Time to First Response (TT1R) in each treatment arm [Time frame: Up to approximately 28 months after the First patient in or scheduled assessment]
• Time to Best Response (TTBR) in each treatment arm [Time frame: Up to approximately 28 months after the First patient in or scheduled assessment]
• Number of participants with treatment emergent adverse events and serious adverse events in each treatment arm [Time frame: Up to approximately 28 months after the First patient in or scheduled assessment]
• Progression-free survival (PFS) in each treatment arm [Time frame: Up to approximately 28 months after the First patient in or scheduled assessment]
• Overall Survival (OS) in each treatment arm [Time frame: Up to approximately 28 months after the First patient in or scheduled assessment]
• Immunogenicity of isatuximab and novel agents [Time frame: Multiple timepoints up to approximately 28 months after the First patient in or scheduled assessment]

Eligibility criteria

Inclusion criteria

• Participant must be 18 years of age inclusive or older.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
• Participants with relapsed or refractory MM who have received at least 2 prior lines of therapy for MM, including PIs and IMiDs (eg, Induction regimen with autologous stem cell transplant followed by maintenance is considered one line).
• RRMM with measurable disease:

• Serum M protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or
• Urine M protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or
• Serum free light chain (sFLC) MM without measurable M protein in serum or urine per previous criteria (serum Ig free light chain ≥10 mg/dL and abnormal serum Ig kappa lambda free light chain ratio <0.26 or >1.65).
• Men or woman or childbearing potential should agree to use contraception.
• Substudy 01, 06: Anti-CD38 therapy naïve or prior exposure to such drugs with a wash out of at least 12 months after the last dose. "Exposure" is defined as at least 2 cycles of therapy.
• Substudies 02, 03: Anti-CD38 therapy naïve or prior exposure to such drugs without being refractory but with a wash out of at least 6 months after the last dose. "Refractory" is defined as progressing within 60 days of last dose of anti-CD38 targeting therapy.
• Substudy 04: Anti-CD38 and anti-B cell maturation antigen (BCMA) therapy (if available) prior exposed participants with RRMM. For anti-CD38, "Exposure" is defined as at least 2 cycles of therapy. For anti-BCMA therapy if available, exposure is defined by at least 2 cycles of therapy.
• Substudy 05: Participants with RRMM with at least 2 cycles of prior exposure to anti-CD38 therapy. For participants to whom BCMA targeted therapy is available (ie, approved in their region and can be reimbursed), at least 2 cycles of prior exposure to a BCMA targeted agent is mandatory.

Exclusion criteria

• Primary systemic amyloid light chain amyloidosis, plasma cell leukemia, monoclonal gammopathy of undetermined significance, or smoldering myeloma.
• Uncontrolled infection within 14 days prior to first study intervention administration.
• Clinically significant cardiac (including valvular) or vascular disease within 3 months prior to first study intervention administration., eg, myocardial infarction, unstable angina, coronary (eg, coronary artery bypass graft, percutaneous coronary intervention) or peripheral artery revascularization, left ventricular ejection fraction <40%, heart failure New York Heart Association Classes III and IV, stroke, transient ischemic attack, pulmonary embolism, other thromboembolic event, or cardiac arrhythmia (Grade 3 or higher by NCI CTCAE Version 5.0).
• Known acquired immunodeficiency syndrome-related illness or known human immunodeficiency virus (HIV) disease requiring antiviral treatment or active hepatitis A.
• Uncontrolled or active hepatitis B virus (HBV) infection.
• Active hepatitis C virus (HCV) infection.
• Any of the following within 3 months prior to first study intervention administration: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease.
• Second malignancy other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma, unless they are successfully treated with curative intent for more than 3 years before first study intervention administration.
• Any anti-MM drug treatment within 14 days before first study intervention administration, including dexamethasone.
• Participants with a contraindication to treatment.
• Vaccination with a live vaccine 4 weeks before the start of the study.
• Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted.
• Hemoglobin <8 g/dL.
• Platelets <50 × 10\^9/L.
• Absolute neutrophil count <1.0 × 10\^9/L.
• Creatinine clearance <30 mL/min/1.73m2.
• Total bilirubin >1.5 × ULN, except for known Gilbert syndrome in which direct bilirubin should be ≤2.5 × ULN.
• Aspartate aminotransferase and/or alanine aminotransferase >3 × ULN.
• Patients with grade 3 or 4 hypercalcemia.

Substudy 01:

-Malabsorption syndrome or any condition that can significantly impact the absorption of pomalidomide.

Substudy 02:

• History of resected/ablated basal or squamous cell carcinoma (SCC) of the skin or carcinoma in situ of the cervix, or other local tumors, even if considered cured by local treatment.
• Therapeutic doses of anticoagulants or antiplatelet agents within 7 days prior to the first dose of SAR439459.
• Prothrombin time or INR >1.5 × upper limit of normal (ULN).

Substudy 03:

• Current corneal epithelial disease except mild punctate keratopathy.
• Patients who have received prior therapy with belantamab mafodotin.

Substudy 04:

• Central nervous system or leptomeningeal disease.
• Medical history of seizure.
• Participants currently receiving hepatically metabolized narrow therapeutic index drugs (eg, digoxin, warfarin) if cannot be closely monitored.
• Active, known, or suspected autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs), except controlled by replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc). The following are not exclusionary: vitiligo, childhood asthma that has resolved, psoriasis that does not require systemic treatment.
• Prior allogeneic hematopoietic stem cell transplant (allo-HSCT).

Substudy 05:

\- Participant unable to swallow tablets.

Substudy 06:

• History of active autoimmune disorders.
• History of autoimmune hemolytic anemia or autoimmune. thrombocytopenia.
• Active graft versus host disease (GVHD) or ongoing immunosuppression for GVHD.
• Prior allogenic hematopoietic stem cell transplant (allo-HSCT).
• Patient with chronic active EBV infection.
• Patients with known history of HLH.
• Hemoglobin < 9 g/dL.
• Prior therapy with any anti-CD47 or anti signal regulatory protein alpha agent.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 5 centers

• Winship Cancer Institute of Emory University- Site Number : 8400010 — Atlanta
• University of Illinois-Chicago - College of Medicine- Site Number : 8400007 — Chicago
• University of Michigan Health System - Ann Arbor- Site Number : 8400004 — Ann Arbor
• Roswell Park Cancer Institute- Site Number : 8400008 — Buffalo
• The Ohio State University- Site Number : 8400012 — Columbus

France · 4 centers

• Investigational Site Number : 2500003 — Paris
• Investigational Site Number : 2500002 — Lille
• Investigational Site Number : 2500001 — Nantes
• Investigational Site Number : 2500004 — Paris

South Korea · 4 centers

• Investigational Site Number : 4100001 — Seoul
• Investigational Site Number : 4100004 — Seoul
• Investigational Site Number : 4100002 — Seoul
• Investigational Site Number : 4100003 — Seoul

Australia · 3 centers

• Investigational Site Number : 0360006 — Wollongong
• Investigational Site Number : 0360002 — Melbourne
• Investigational Site Number : 0360001 — Richmond

Israel · 3 centers

• Investigational Site Number : 3760002 — Jerusalem
• Investigational Site Number : 3760003 — Ramat Gan
• Investigational Site Number : 3760001 — Tel Aviv

Germany · 2 centers

• Investigational Site Number : 2760006 — Frankfurt
• Investigational Site Number : 2760008 — Lübeck

Greece · 2 centers

• Investigational Site Number : 3000002 — Athens
• Investigational Site Number : 3000001 — Athens

Italy · 1 center

• Investigational Site Number : 3800001 — Meldola

Norway · 1 center

• Investigational Site Number : 5780001 — Oslo

Puerto Rico · 1 center

• Puerto Rico Medical Research Center- Site Number : 8400005 — Hato Rey

Identifiers

NCT: NCT04643002 · ACT16482 · U1111-1244-2598 · 2024-514988-25 · 2020-003024-16

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗